Enterome, a clinical-stage biopharmaceutical company developing novel OncoMimics immunotherapies, has raised $19 million in a new private financing round.
The funds will support clinical development of its lead candidate, EO2463, for treating indolent non-Hodgkin lymphoma (iNHL), and help prepare the company’s pipeline for late-stage trials.
The financing includes $9 million from The Institute for Follicular Lymphoma Innovation (IFLI), a nonprofit dedicated to advancing treatments for follicular lymphoma. Of that amount, $5 million will be disbursed immediately, with an additional $4 million tied to future milestones.
Another $10 million came from returning investors, including The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP), SymBiosis Capital Management, Seventure Partners, Lundbeckfonden BioCapital, and Primo Capital.
Funding Fuels Phase I/II Expansion for EO2463 in Follicular Lymphoma
The proceeds will be used to expand and finalize the ongoing Phase I/II SIDNEY trial (NCT04669171) of EO2463, Enterome’s flagship OncoMimics candidate. The study evaluates EO2463 as a monotherapy and in combination with standard treatments in patients with follicular lymphoma and marginal zone lymphoma.
EO2463 is designed to selectively target malignant B cells through synthetic peptides that mimic B-cell markers (CD20, CD22, CD37, CD268). The candidate incorporates four CD8+ epitopes plus a universal CD4+ helper peptide (UCP2), enabling a coordinated T-cell response. Enterome’s approach bypasses immune tolerance mechanisms like thymic deletion, allowing the immune system to mount a potent, targeted attack against cancer cells.
Preliminary results from the SIDNEY trial—especially in the “watch-and-wait” iNHL cohort—have been described as highly encouraging. This patient population, typically not treated due to the toxicity of standard therapies, has shown responses to EO2463 with excellent safety and tolerability, according to Enterome. The data was shared at the American Society of Hematology (ASH) meeting in December 2024.
Pierre Bélichard, CEO of Enterome, stated, “EO2463 has shown robust clinical efficacy and exceptional safety and tolerability—especially impressive for such a potent immunotherapy. This offers a new hope for patients and a rare opportunity to create an entirely new market segment.”
Regulatory Engagement and Market Readiness
Enterome has recently held positive meetings with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), where the company outlined a regulatory path to market for EO2463 in “watch-and-wait” iNHL patients. The candidate’s safety profile and mechanism of action make it particularly well suited for this unmet need, offering patients an effective therapy without the risks of conventional treatments.
Michel Azoulay, MD, Chief Medical Officer at IFLI, said, “EO2463 represents a novel class of synthetic, off-the-shelf immunotherapeutics. We are particularly interested in supporting Enterome’s efforts to demonstrate EO2463’s clinical efficacy across multiple lines of therapy, including relapsed and refractory settings.”
Data from a new combination cohort—EO2463 plus standard of care in relapsed/refractory iNHL—will be presented at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21. These data build on earlier results from the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, which also suggested biomarker-driven patient selection may optimize EO2463’s impact.
Laure Gruenbaum, Chief Scientific Officer at LLS, noted, “We are particularly excited to help advance EO2463, which has shown promising signs of efficacy as monotherapy with excellent safety in ‘watch-and-wait’ iNHL patients, who currently have no approved treatment options.”
